All share a xanthine ring, the core chemical framework of caffeine and related plant-derived purine alkaloids, but the compounds displayed markedly different biological effects in the injury models. The experiment deliberately used two complementary approaches: excessive L-glutamate, abbreviated L-GLU, to mimic excitotoxic neuronal injury, and hydrogen peroxide to generate oxidative stress. This design revealed that protection depended on the type of damage, the severity of injury, the concentration used and the duration of exposure.

Before testing protection, the team established concentrations that did not themselves reduce cell viability. Cytotoxicity was measured with the MTT colorimetric assay, in which metabolic conversion of a tetrazolium salt to formazan provides a readout associated with viable cells. Each concentration was evaluated in six replicates, and the selected non-toxic or maximum safe concentrations differed markedly among compounds: they ranged from 0.1 micromolar for Jas 1 to 100 micromolar for Jas 10.

These compound-specific ranges are important because the later percentages describe protection relative to matched injury controls, not equivalent absolute doses or evidence that every member is equally potent. In the L-GLU model, cells were challenged with 60 millimolar L-GLU after pretreatment with the test compounds, and viability was assessed by MTT after a further 24 hours. Jas 9 was the only derivative to produce statistically significant protection.

At 50 micromolar, it improved viability by approximately 7% relative to the L-GLU-only group, while 100 micromolar produced an improvement of about 10%; the reported significance levels were p < 0.05 and p < 0.01, respectively. The other nine compounds did not significantly improve survival under those conditions. The result indicates that modifying caffeine’s structure did not automatically yield broad protection against excitotoxicity.

That contrast became more pronounced in the hydrogen-peroxide experiments, which were conducted at two injury levels. A severe model used 6 micromolar hydrogen peroxide and reduced viability by roughly 50%, while a mild model used 5 micromolar and produced an approximately 20% loss. With two hours of compound pretreatment, Jas 2, Jas 5, Jas 6 and Jas 8 showed statistically significant cytoprotection in the severe model.

The largest reported increases were about 18% for Jas 8 at 0.1 micromolar and Jas 5 at 0.1 micromolar. These gains were measured relative to the damaged control and did not restore viability to the level of untreated cultures. Extending pretreatment from two hours to 24 hours did not produce a uniformly stronger response.

Under severe oxidative injury, Jas 8 at 0.1 micromolar and Jas 5 at 1 micromolar remained protective, each corresponding to an improvement of approximately 7%. The authors interpreted the continued activity of Jas 8 as evidence that its effect could be stable under prolonged exposure, but the measured benefit under the severe, extended-preratment condition was smaller than some effects seen with shorter pretreatment. The experiment therefore does not support a simple claim that longer treatment always produces greater protection.

In the mild oxidative-stress model, significant protection was reported for Jas 2, Jas 7, Jas 8 and Jas 10 at selected concentrations. Jas 8 at 0.1 and 1 micromolar, Jas 2 at 1 micromolar and Jas 10 at 10 micromolar were significant at p < 0.01; Jas 7 at 10 micromolar and Jas 2 at 10 micromolar were also reported as significant. Among them, Jas 8 produced the largest increase in cell viability.

The fact that different compounds were active in mild and severe injury, at different concentrations and with different pretreatment schedules, points to a narrow and context-dependent activity profile rather than a straightforward linear dose-response relationship. The authors consequently identified Jas 8 as a lead candidate for further pharmacological optimization and evaluation in more advanced experimental systems. The researchers then examined how the leading compounds affected reactive oxygen species using the fluorescent probe DCFH-DA.

Cells were treated with the test compounds and exposed to 6 micromolar hydrogen peroxide for either 30 or 60 minutes. Jas 8 significantly lowered fluorescence at 0.1, 1 and 10 micromolar in both assays. At 1 micromolar, the compound reduced the signal by approximately 50% after 30 minutes of hydrogen-peroxide exposure and by about 70% after 60 minutes, compared with cells exposed to hydrogen peroxide alone.

These observations provide experimental evidence that Jas 8 can reduce the intracellular oxidative signal detected by this assay under the tested conditions. The results were reported as means with standard deviations from three independent experiments, with each condition tested in six replicates. Jas 8’s overall profile made it the study’s lead candidate, whereas Jas 9 was distinguished by its activity against L-GLU injury and Jas 5 showed selected protective effects.

The xanthine structure provides a possible mechanistic connection to adenosine-receptor modulation, because caffeine is a nonselective adenosine-receptor antagonist, and the authors suggest that this pathway might contribute alongside antioxidant activity. The experiments reported here did not directly test that mechanism. They also do not establish that the compounds cross the blood–brain barrier, reach therapeutic concentrations in the human brain, avoid toxicity or improve symptoms in people.

Their relevance to neurodegenerative disease is therefore limited to the cellular findings and the experimental rationale for further investigation, rather than demonstrated clinical benefit. Overall, the study supports a mechanism-specific conclusion: caffeine-derived structures can exhibit different protective profiles depending on whether cells face oxidative or excitotoxic injury. Jas 8 produced the most consistent activity in the oxidative-stress experiments, combining improved viability with substantial reductions in the DCFH-DA signal, while Jas 9 alone was significant in the L-GLU model.

The results identify Jas 8 as a candidate for further optimization, but they do not yet establish its effectiveness, safety or mechanism in more complex biological systems.

Subject of Research: In vitro neuroprotective and antioxidant effects of caffeine-derived compounds in human neuroblastoma cells

Article Title: Caffeine-derived 8-α-methylthioglycolic acid compounds as promising neuroprotective agents in cellular models of neurotoxicity

Article References: Stefanova, D., Mitkov, Y., & Tzankova, V. (2026). Caffeine-derived 8-α-methylthioglycolic acid compounds as promising neuroprotective agents in cellular models of neurotoxicity. Pharmacia, 73, Article e195774. https://doi.org/10.3897/pharmacia.73.e195774

Image Credits: AI Generated

DOI: 10.3897/pharmacia.73.e195774

Keywords: caffeine derivatives, neuroprotection, oxidative stress, excitotoxicity, SH-SY5Y cells, xanthines, reactive oxygen species, cell viability, hydrogen peroxide, laboratory research, Caffeine-derived, methylthioglycolic

The research team, led by Balázs Pál at the University of Debrecen, worked with a rare and precious resource: intact neocortical tissue removed during neurosurgery for brain tumors or metastases. These samples, collected from 25 patients ranging from 38 to 79 years old, allowed the scientists to perform patch-clamp recordings on living human neurons — an opportunity that few laboratories in the world have. Using whole-cell voltage clamp at a holding potential of −60 millivolts, the team recorded layer II-III pyramidal neurons and measured both fast synaptic events and the slow, sustained currents generated by ambient glutamate acting outside the synapse.

Glutamate is the brain’s dominant excitatory neurotransmitter, responsible for roughly 70 percent of all synaptic transmission. But its influence extends far beyond the synaptic cleft. In the extrasynaptic space, glutamate exists at concentrations thousands of times lower than inside a synapse — in the nanomolar to micromolar range rather than the millimolar range — yet it can still activate NMDA, AMPA, and metabotropic glutamate receptors located on neuronal membranes outside active synapses. These extrasynaptic receptors often differ in subunit composition from their synaptic counterparts, with NMDA receptors containing the GluN2B subunit being particularly enriched at extrasynaptic sites. The clearance of this ambient glutamate falls almost entirely to astrocytes, star-shaped glial cells that express the excitatory amino acid transporters EAAT1 and EAAT2, which together remove the vast majority of extracellular glutamate from the brain.

When the researchers applied DL-TBOA, a potent blocker of these glutamate transporters, to human neocortical slices, they observed two distinct phenomena. First, they recorded slow inward currents (SICs) — brief, phasic depolarizing events lasting hundreds of milliseconds that arise from the synchronous activation of extrasynaptic NMDA receptors by glutamate released from astrocytes. Second, and more remarkably, they detected a tonic inward current: a sustained shift in the holding current that persisted throughout the recording, averaging −56.8 ± 25.88 picoamperes across 16 neurons. This tonic current was significantly greater than the spontaneous fluctuation of the holding current measured before drug application, which averaged only 0.55 ± 1.13 picoamperes.

The pharmacological dissection of this tonic current revealed a surprising complexity. When the researchers applied ifenprodil, a selective antagonist of GluN2B-containing NMDA receptors, the tonic current was only partially reversed — dropping from −103.7 ± 54.2 picoamperes to −56.64 ± 33.57 picoamperes, a change that did not reach statistical significance. In contrast, SICs were almost completely eliminated by the same drug. This dissociation suggests that while both phenomena depend on NMDA receptor activation, the receptors mediating the tonic current are not exclusively GluN2B-containing. When the researchers applied D-AP5, a broad-spectrum NMDA receptor antagonist, the tonic current was fully abolished — dropping from −59.2 ± 28.72 picoamperes to −0.3 ± 2.59 picoamperes — confirming that NMDA receptors are essential for its generation.

One of the most striking findings emerged when the researchers correlated tonic current amplitude with patient age. The magnitude of the DL-TBOA-elicited tonic current was inversely proportional to the age of the donor, with a statistically significant correlation (p = 0.037, r² = 0.26). In patients over 70 years old, the tonic current was essentially undetectable. This age-dependent decline mirrors the team’s previous work on SICs, which also showed a dramatic reduction with advancing age in human tissue — a pattern that contrasts sharply with rodent studies, where only mild age-related changes in SIC frequency have been observed. The researchers suggest that this decline may reflect a combination of factors, including reduced GluN2B subunit expression, altered EAAT transporter function, and age-related changes in astrocyte morphology that modify glutamate diffusion pathways in the extracellular space.

The relationship between SICs and the tonic current proved to be quantitative as well as qualitative. When the researchers re-analyzed SIC data from their previous study and plotted the charge transfer of SICs per minute against the magnitude of the tonic current, they found a strong positive correlation (p < 0.0001, r² = 0.636, n = 19). Neurons that generated more SIC charge also carried larger tonic currents, suggesting that both phenomena arise from the same fundamental process — the accumulation of ambient glutamate in the extrasynaptic space — but manifest differently depending on the spatial relationship between glutamate release sites and receptor populations. The researchers propose that when glutamate diffuses over short distances, it produces discrete SICs, while longer diffusion pathways or more distributed receptor activation summate into a sustained tonic current.

Power spectral analysis of the baseline noise revealed further distinctions between the two phenomena. DL-TBOA application increased the power amplitude of baseline oscillations from 0.37 ± 0.1 to 3.95 ± 1.13 pA²/Hz, an effect that was reversed by D-AP5 but only partially reduced by ifenprodil. The frequency at the power maximum remained unchanged, suggesting that the increased noise reflected stochastic NMDA receptor openings rather than a shift in oscillation frequency. When the researchers compared the oscillatory properties of SIC declining phases with those of the tonic current, they found that SIC declining phases exhibited significantly greater power amplitude (6.46 ± 1.43 vs. 1.75 ± 0.71 pA²/Hz) and higher frequency (13.66 ± 1.56 vs. 5.72 ± 0.94 Hz), providing electrophysiological evidence that these are partially separable phenomena with distinct receptor activation kinetics.

Two control experiments strengthened the argument that the tonic current is pathological rather than physiological. First, when the researchers simply removed magnesium from the recording solution — a manipulation that dramatically increases SIC activity by relieving the voltage-dependent magnesium block of NMDA receptors — no tonic inward current appeared. The holding current remained essentially unchanged, averaging 0.46 ± 1.13 picoamperes in normal artificial cerebrospinal fluid and 0.25 ± 1.11 picoamperes in magnesium-free solution. Second, when the researchers applied GT949, a positive allosteric modulator of EAAT2 that enhances glutamate uptake, they expected to see a tonic outward current if a baseline tonic inward current existed under control conditions. Instead, no significant current change was detected. Together, these results indicate that under normal physiological conditions, human neocortical pyramidal neurons do not carry a measurable NMDA-dependent tonic inward current.

The clinical implications of this finding are significant. Tonic neuronal depolarization driven by excess extracellular glutamate is a known contributor to ischemic stroke, traumatic brain injury, and cortical spreading depolarization — a massive depolarizing wave that sweeps across cortical networks during these conditions. The researchers hypothesize that the tonic inward current they have characterized may represent one of the cellular mechanisms underlying this pathological depolarization, particularly given that its magnitude declines with age in parallel with the known age-related decrease in cortical susceptibility to spreading depolarization. In gliomas, extracellular glutamate levels are elevated, and the tonic current may contribute to tumor-related hyperexcitability. The finding that this current requires transporter inhibition rather than existing constitutively suggests that therapeutic strategies aimed at maintaining or enhancing EAAT function could protect vulnerable neurons from the sustained depolarization that drives excitotoxic cell death in a range of neurological diseases.

Subject of Research: NMDA receptor-mediated tonic inward currents elicited by glutamate transporter inhibition in human neocortical pyramidal neurons

Article Title: NMDA receptor mediated tonic excitatory currents are elicited by EAAT inhibition on human neocortical pyramidal neurons

Article References: Márton, B., Ecsedi, L., Pocsai, K., Douida, A., Lamsa, K., Hutóczki, G., Klekner, Á., & Pál, B. (2026). NMDA receptor mediated tonic excitatory currents are elicited by EAAT inhibition on human neocortical pyramidal neurons. Frontiers in Synaptic Neuroscience, 18, Article 1844197. https://doi.org/10.3389/fnsyn.2026.1844197

Image Credits: AI Generated

DOI: 10.3389/fnsyn.2026.1844197

Keywords: NMDA receptor, glutamate transporters, EAAT, astrocytes, human neocortex, pyramidal neurons, tonic inward current, slow inward currents, excitotoxicity, cortical spreading depolarization, aging brain, electrophysiology

Connexin 36 (Cx36) forms electrical synapses that allow direct cytoplasmic continuity between adjacent retinal neurons, enabling the rapid exchange of ions and small metabolites. In the outer retina, Cx36-containing gap junctions mediate rod-cone coupling and regulate visual signal integration, while in the inner retina, they contribute to electrical coupling between retinal ganglion cells and amacrine cells. These channels are essential for temporal precision in visual processing, enhancing signal-to-noise ratio and firing synchrony. However, under pathological conditions such as excitotoxicity, the same gap junctions that normally support healthy signal transmission can become conduits for the spread of toxic signals—including calcium overload and pro-apoptotic molecules—from injured neurons to their healthy neighbors.

The research team, led by Adrian Smędowski at the Medical University of Silesia in Katowice, Poland, used immortalized 661W murine photoreceptor cells transfected with GFP-tagged Cx36 to visualize the protein’s intracellular distribution under controlled stress conditions. The 661W cell line, derived from mouse cone photoreceptors, expresses cone-specific markers and retains light responsiveness through cGMP modulation, making it a physiologically relevant model for studying retinal photoreceptor biology. The researchers chose this model because it provides a more relevant retinal phenotype compared to other neuron-like cell lines, though they acknowledge that findings from an immortalized cell line must ultimately be validated in intact retinal tissue.

To probe the degradation pathways responsible for Cx36 turnover, the team employed two complementary pharmacological approaches. First, they used bafilomycin A1, a macrolide antibiotic that disrupts autophagic flux by blocking V-ATPase-dependent acidification of lysosomes and inhibiting autophagosome-lysosome fusion. Second, they exposed the cells to N-methyl-D-aspartate (NMDA) to induce excitotoxic stress, mimicking the glutamate-mediated overactivation that contributes to neuronal damage in retinal neurodegenerative diseases. By applying these interventions separately and in combination with Cx36 overexpression, the researchers could dissect the relative contributions of the autophagy-lysosome pathway and the ubiquitin-proteasome system (UPS) to connexin proteostasis.

The results revealed a striking pattern of proteostatic reorganization. Following bafilomycin A1 treatment, immunofluorescence analysis showed intracellular accumulation of the autophagy adaptor protein SQSTM1/p62, with signal intensities increasing approximately 1.5- to 2-fold compared to controls (n = 3, p < 0.05). Under normal conditions, p62 selectively binds polyubiquitinated protein aggregates and delivers them to autophagosomes via interaction with LC3, facilitating their degradation upon fusion with lysosomes. When this pathway is blocked, p62 itself accumulates because it can no longer be cleared. The researchers also observed a marked upregulation of PSMA1, a structural subunit of the 20S proteasome core particle, suggesting a potential compensatory shift toward proteasomal degradation when lysosomal clearance is compromised.

Perhaps most intriguingly, the team detected elevated levels of RAB11A, a small GTPase associated with the recycling endosome pathway. RAB11A controls the return of internalized receptors from recycling endosomes to the plasma membrane and contributes to vesicular trafficking processes underlying endosomal sorting. Its increased expression may reflect an adaptive cellular response to impaired protein degradation, potentially contributing to altered intracellular trafficking and redistribution of proteins—including Cx36—under stress conditions. Notably, the researchers did not observe changes in other endosomal markers such as EEA1, RAB5A, or RAB9A, suggesting that the recycling pathway specifically, rather than the broader endocytic machinery, is recruited in response to lysosomal blockade.

When the researchers turned to the excitotoxicity model, they found that NMDA treatment was associated with increased ubiquitin accumulation, particularly in Cx36-overexpressing cells. Ubiquitin serves as a molecular tag that marks damaged or misfolded proteins for degradation by the 26S proteasome through a cascade involving E1 ubiquitin-activating enzymes, E2 ubiquitin-conjugating enzymes, and E3 ubiquitin ligases. The enhanced ubiquitin signal in Cx36-expressing cells exposed to NMDA suggests that excitotoxic conditions compromise Cx36 stability and promote its ubiquitination, indicating enhanced proteostatic stress specifically in cells bearing higher loads of the gap junction protein. Interestingly, Cx36 immunoreactivity remained predominantly cytoplasmic with a punctate distribution pattern, and no major redistribution was observed following NMDA treatment.

The implications of these findings extend beyond basic cell biology. Previous studies have demonstrated that blocking gap junctions under excitotoxic or ischemic conditions can improve retinal ganglion cell survival by up to 70 percent, underscoring the critical role of intercellular communication in propagating neuronal injury. Genetic knockout studies have further shown that eliminating Cx36 significantly reduces retinal ganglion cell death under excitotoxic stress. The current work adds a new dimension to this understanding by suggesting that modulating Cx36 turnover or stabilization—rather than simply upregulating or downregulating its expression—may represent a more effective neuroprotective strategy. By targeting the proteostatic machinery that controls connexin degradation, it may be possible to fine-tune gap junction abundance and coupling strength in ways that preserve normal visual signal transmission while limiting the pathological spread of toxic signals.

The study’s authors are careful to note several important limitations. The immunofluorescence-based approach, while providing unique spatial resolution for assessing intracellular distribution, does not allow precise quantification of total protein expression. Definitive confirmation of impaired autophagic flux would require LC3-II turnover analysis, which was not performed in this study. Similarly, the observed PSMA1 upregulation suggests but does not prove functional proteasome involvement. The use of Cx36 overexpression itself may influence intracellular proteostasis, and the cytoplasmic distribution of the tagged protein likely reflects overexpression-driven accumulation within the endoplasmic reticulum or vesicular compartments rather than functional gap junction localization at the plasma membrane. Future work incorporating Western blotting, LC3-II flux assays, proteasome activity measurements, live-cell imaging, and validation in retinal explants or animal models will be essential to confirm and extend these preliminary observations.

Nevertheless, the study opens a compelling new avenue for investigating retinal neurodegeneration. Both glaucoma and age-related macular degeneration are characterized by progressive dysfunction of proteostatic mechanisms—whether through oxidative stress in the retinal pigment epithelium, mitochondrial dysfunction in retinal ganglion cells, or chronic neuroinflammation. If connexin proteostasis proves to be a modifiable node in these degenerative cascades, targeted pharmacological interventions aimed at specific degradation pathways could offer a precision approach to preserving vision. The researchers suggest that better understanding of these subcellular mechanisms will potentially allow the design of precisely targeted treatments in the future, transforming our approach to diseases that currently rob millions of people worldwide of their sight.

Subject of Research: Proteostatic regulation of the neuronal gap junction protein connexin 36 in photoreceptor cells under excitotoxic stress

Article Title: Gap junction protein connexin 36 proteostatic mechanisms in photoreceptor cells subjected to excitotoxic stress

Article References: Katan, M., Mróz, K., Pacwa, A., Lewin-Kowalik, J., & Smędowski, A. (2026). Gap junction protein connexin 36 proteostatic mechanisms in photoreceptor cells subjected to excitotoxic stress. Acta Biochimica Polonica, 73, Article 16091. https://doi.org/10.3389/abp.2026.16091

Image Credits: AI Generated

DOI: 10.3389/abp.2026.16091

Keywords: connexin 36, gap junctions, photoreceptors, excitotoxicity, autophagy, ubiquitin-proteasome system, retinal degeneration, glaucoma, age-related macular degeneration, p62/SQSTM1, RAB11A, proteostasis

The answer, distilled from three decades of clinical research, is more nuanced than the simple dictum that time equals damage. The reviewers found that longer seizure duration was more consistently and more independently associated with worse functional outcome, meaning lasting motor or cognitive impairment, than with mortality itself. The link between duration and death, while present in many individual studies, proved weaker and less reliable once other determinants were taken into account. The reason, the authors argue, is that mortality in status epilepticus is shaped by a crowded field of competing forces: the underlying cause of the seizure, the patient’s premorbid vulnerability, and the severity of systemic complications such as hypoxia, hyperthermia, and metabolic derangement. Duration, in other words, is only one voice in a chorus.

To appreciate why this finding matters, it helps to understand what happens to the brain during prolonged seizure activity. Experimental work dating back to the classic 1973 studies by Meldrum and colleagues in paralyzed, artificially ventilated baboons demonstrated that even when systemic factors are controlled, prolonged seizures injure neurons. Later human autopsy studies, including work by Fujikawa and colleagues published in 2000, documented neuronal loss in patients who died of status epilepticus without systemic complications. Excitotoxic mechanisms, in which excessive glutamate signaling floods neurons with calcium, combined with GABAergic receptor internalization that makes seizures progressively resistant to standard antiseizure drugs, create a vicious cycle in which the seizure itself remodels the circuits that should terminate it. This pharmacoresistance is precisely why early treatment matters: benzodiazepines work far better in the first minutes than after an hour of continuous firing.

Yet the new review exposes a methodological Achilles heel that has haunted this literature since its inception. The definition and measurement of seizure duration varied enormously across the forty-three included studies. Some counted duration from the onset of clinically visible convulsions; others anchored it to electrographic onset on continuous EEG. Some measured the time to seizure termination under treatment; others summed cumulative seizure time across recurrences. Analytical strategies diverged just as widely, with some studies treating duration as a continuous variable and others dichotomizing patients at thresholds that ranged from thirty minutes to several hours, often without explicit justification. The reviewers assessed risk of bias with the QUIPS tool and synthesized the outcome-specific associations narratively, precisely because the heterogeneity made a formal meta-analysis of pooled effect estimates untenable.

The mortality signal illustrates the problem vividly. Thirty-one of the included studies examined death as an outcome, spanning settings from population-based cohorts in Richmond, Virginia and Auckland, New Zealand to intensive care units across Europe and tertiary centers in Asia. Landmark work such as the 1994 study by Towne and colleagues on determinants of mortality, and more recent analyses of long-term survival trajectories using the ACD score, consistently identified etiology, age, and level of consciousness as dominant predictors. Against those heavyweight variables, duration often lost statistical independence. A brief seizure caused by a massive stroke can be lethal, while a prolonged but eventually controlled seizure in a young patient with a reversible metabolic trigger may leave no lasting deficit. Duration, the review concludes, should be read as a context-dependent prognostic marker rather than an absolute threshold.

Functional outcome told a different and arguably more coherent story. Twenty-six studies assessed motor or cognitive impairment after status epilepticus, and here longer duration aligned more reliably with worse results. Studies of prolonged and super-refractory status epilepticus, including cohorts from Basel and Erlangen and the French multicenter experience reported by Legriel and colleagues, found that patients whose seizures persisted for hours or days faced substantially higher risks of dependency and cognitive decline. Cognitive studies using formal neuropsychometric instruments, such as the analysis by Adachi and colleagues with the Wechsler Adult Intelligence Scale-Revised, documented measurable intellectual deterioration after prolonged episodes. The biological plausibility is strong: the longer networks remain in an ictal state, the more extensive the excitotoxic injury to hippocampal and neocortical structures that subserve memory and motor control.

Refractoriness, the tendency of a seizure to resist first- and second-line therapy, added a third dimension. Only seven studies examined this outcome, so the evidence base is thin, but the reviewers describe it as limited yet consistent: prolonged seizures were linked to treatment resistance. This relationship is bidirectional in practice, because delayed treatment extends duration and extended duration breeds pharmacoresistance through receptor trafficking. A 2021 study by Gutiérrez-Viedma and colleagues showed that therapy delay in status epilepticus extends its duration and worsens prognosis, while work by Guterman and colleagues demonstrated that the pattern of treatment progression itself shapes the burden of illness. Recent analyses, including a 2026 study suggesting that treatment adequacy outweighs treatment sequence in nonconvulsive status epilepticus, reinforce the message that what clinicians do, and how quickly, matters as much as the clock alone.

The review also grapples with the thorny question of where a seizure begins and ends, a problem that a companion 2026 scoping review by Khan and colleagues tackled directly by proposing a framework for standardizing the endpoint of status epilepticus. In convulsive seizures, onset is usually timed from the first observable motor manifestation, but in nonconvulsive status epilepticus, which can occur without any visible convulsion, onset may only be revealed by EEG, sometimes hours after the true start. Recurrence rules differ too: is a seizure that stops and restarts within an hour one prolonged event or two separate ones? Each choice changes the measured duration and can flip a patient across a categorical threshold. The reviewers call for standardized onset and termination criteria, explicit recurrence rules, and harmonized statistical modeling so that future studies can be compared and combined meaningfully.

For clinicians at the bedside, the practical takeaways remain reassuringly aligned with long-standing practice. Time is still brain, and the pharmacological window for terminating a seizure with benzodiazepines closes quickly. But the review cautions against reading duration as a standalone death sentence or a rigid cutoff for aggressive escalation. A patient’s trajectory is jointly determined by the electroclinical phenotype of the seizure, whether convulsive, focal, nonconvulsive, or the devastating post-anoxic variety, by the underlying etiology, whether acute structural injury, infection, autoimmune encephalitis, or drug withdrawal, and by systemic severity. Prognostic scores that integrate these domains, rather than duration alone, offer the most honest guidance for counseling families and calibrating intensive care.

For researchers, the message is a call to methodological discipline. The Pisa team’s synthesis, conducted under PRISMA 2020 reporting standards and published as Volume 273, article 644 of the Journal of Neurology, does not deliver a single magic number, and it deliberately refuses to invent one. Instead, it maps the terrain: duration matters most for functional recovery, less decisively for survival, and plausibly for refractoriness, but only when measured and modeled consistently. As continuous EEG monitoring spreads and machine-learning approaches to seizure detection mature, the raw material for precise duration measurement is finally becoming available at scale. The challenge now, the authors argue, is to agree on the rules of the game, so that the next systematic review can move beyond narrative synthesis and tell clinicians exactly how many minutes separate a good outcome from a devastating one.

Subject of Research: Association between duration of status epilepticus and mortality, functional outcome, and treatment refractoriness in adults

Article Title: Associations between duration of status epilepticus and clinical outcomes in adults: a systematic review

Article References: Iannaccone, F., Scarpitta, C., De Rossi, E., Milano, C., Turco, F., Bonanni, E., Fornai, F., Ceravolo, R., & Pizzanelli, C. (2026). Associations between duration of status epilepticus and clinical outcomes in adults: a systematic review. Journal of Neurology, 273(10), Article 644. https://doi.org/10.1007/s00415-026-14179-0

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14179-0

Keywords: status epilepticus, seizure duration, mortality, functional outcome, refractory status epilepticus, prognosis, systematic review, neurology, epilepsy, electroencephalography, neurocritical care, excitotoxicity

The research, led by Sylvain Gourier and Marwan Bouras of Brest University Hospital Centre in France, together with colleagues in Quebec and Nantes, set out to answer a deceptively simple question: when AMPA receptor antagonists are administered after a traumatic brain injury in mammals, do they actually make things better? The team searched three major biomedical databases, MEDLINE, Embase and Web of Science, and screened 410 records to arrive at a final set of eleven studies that met their strict inclusion criteria. Only mammalian in vivo experiments in which an AMPA receptor antagonist was given after the injury and compared against a vehicle control, no treatment, or an alternative intervention were eligible, a design intended to mirror as closely as possible the clinical scenario in which a patient arrives at a hospital after the insult has already occurred.

The biological rationale behind this line of investigation runs deep. When the brain is subjected to mechanical trauma, damaged and dying cells flood the extracellular space with glutamate, the principal excitatory neurotransmitter of the central nervous system. Under normal conditions, glutamate transmission is tightly regulated, but after injury the excess glutamate overstimulates its receptors, provoking a cascade known as excitotoxicity. Calcium floods into neurons through ion channels, mitochondrial function collapses, free radicals accumulate, and cells that survived the initial blow die a slow secondary death over hours to days. Because this secondary injury unfolds on a timescale that leaves a therapeutic window, interrupting it with receptor blockers has long been an attractive strategy. Previous attempts targeting the related NMDA receptor ultimately failed in human trials, but the AMPA receptor, which mediates the fast component of excitatory synaptic transmission and can become calcium-permeable after injury, has re-emerged as a distinct and possibly more tractable target.

To conduct the meta-analysis, two reviewers independently screened the candidate studies, extracted the data and appraised methodological quality and risk of bias using two established instruments: the CAMARADES checklist, developed specifically for pooling animal data from experimental studies, and the SYRCLE tool, which probes sources of bias in laboratory animal research. The primary outcome was neurobehavioural performance, assessed across three distinct domains: neurological deficit, cognition and memory, and motor coordination. Secondary outcomes included the severity of brain lesions, mortality, and inflammatory biomarkers. The team applied random-effects meta-analysis, expressing treatment effects as standardized mean differences, a statistical approach that allows results measured on different behavioural scales in different laboratories to be combined into a single estimate.

The headline result is striking for cognition. Across five studies, AMPA receptor antagonists produced a large improvement in cognition and memory, with a standardized mean difference of 1.53 and a tight 95 percent confidence interval running from 1.06 to 2.01. Perhaps more importantly for the credibility of the finding, the statistical heterogeneity across these studies was almost nonexistent, with an I-squared value of just 3 percent, meaning the effect was remarkably consistent from one experiment to the next. In a field where preclinical results often vary wildly between laboratories, this kind of uniformity is rare and lends considerable weight to the conclusion that AMPA blockade genuinely protects the injured, memory-forming circuits of the hippocampus and surrounding structures.

Neurological deficit scores also favoured the drug-treated animals, with a standardized mean difference of 1.28 across four studies, although the confidence interval here, stretching from 0.05 to 2.50, barely excludes zero and the heterogeneity was high at 78 percent, signalling that study designs, drug choices or injury models differed in ways that materially affected the results. Motor coordination told a different story altogether: pooling two studies yielded a standardized mean difference of minus 1.00 with a confidence interval spanning from minus 2.96 to 0.96 and extreme heterogeneity of 83 percent, which the authors interpret as no reliable benefit for motor function. This dissociation between cognitive and motor outcomes is biologically plausible, since AMPA receptor signalling is central to synaptic plasticity in memory circuits, while motor recovery after trauma may depend on mechanisms that pharmacological receptor blockade cannot rescue, or may even require intact AMPA-mediated signalling for compensatory plasticity to occur.

Beyond behaviour, the drugs left visible marks on the injured brain itself. In seven studies measuring lesion severity, AMPA receptor antagonists significantly reduced the extent of tissue damage, with a standardized mean difference of minus 1.39 and moderate heterogeneity of 53 percent. The included experiments spanned several generations of compounds, from early competitive antagonists such as NBQX and the quinoxalinediones ZK200775 and YM872 to the noncompetitive agent talampanel and, more recently, perampanel, the first AMPA antagonist approved for clinical use as an antiepileptic drug. Several of the newer studies also documented consistent reductions in inflammatory biomarkers, aligning with work showing that perampanel dampens oxidative stress, pyroptosis and neuroinflammation through pathways involving molecules such as Sirt3, and protects the neurovascular unit that maintains the blood-brain barrier. Mortality, by contrast, showed no significant effect, a reminder that preventing cellular cascades of damage does not necessarily translate into survival advantages in these models.

The authors are careful to frame their conclusions within the limits of the evidence. Some results, particularly those for neurological deficit and motor coordination, rest on small numbers of studies with substantial statistical heterogeneity and should be interpreted with caution. Publication bias, a chronic problem in animal research in which positive results are more likely to be published than negative ones, may also inflate the apparent effect sizes. The protocol was prospectively registered on the Open Science Framework in April 2025, and the team followed PRISMA reporting guidelines, measures that improve transparency but cannot conjure data that were never collected. The related clinical picture remains sobering: an earlier systematic review by the same senior group found that excitatory amino acid inhibitors have not demonstrated clear benefit in human trials of acute traumatic brain injury, and the field’s history with NMDA antagonists, which failed despite promising animal data, haunts every new preclinical success.

Yet the timing of this analysis is propitious, because the preclinical evidence now intersects with a genuinely new clinical opportunity. Perampanel is already approved and in widespread use for epilepsy, with a growing literature documenting its safety, tolerability, brain penetration and even intravenous formulations suitable for critically ill patients. A phase-two multicentre randomised clinical trial, known as PEACE-TBI, has been designed in Japan to test whether perampanel can alleviate secondary injury after traumatic brain injury in humans. Against that backdrop, the present meta-analysis provides exactly the kind of rigorous synthesis of the animal evidence that trial designers and funders need, confirming biological plausibility for the neurobehavioural and lesion-reducing effects while honestly flagging the outcomes, motor recovery and mortality, where the signal is weak or absent. Whether AMPA receptor antagonists can finally break the decades-long cycle of failed neuroprotection in traumatic brain injury will be decided in patients, but the laboratory evidence assembled here suggests the hypothesis deserves its day in the clinic.

Subject of Research: Efficacy of AMPA receptor antagonists in preclinical animal models of traumatic brain injury

Article Title: AMPA Receptor Antagonists in Preclinical Models of Traumatic Brain Injury: A Systematic Review and Meta-analysis of Animal Studies

Article References: Gourier, S., Morin, C., Gargadennec, T., Turgeon, A. F., Poulain, C., Roquilly, A., Caillard, A., Langeron, O., & Bouras, M. (2026). AMPA Receptor Antagonists in Preclinical Models of Traumatic Brain Injury: A Systematic Review and Meta-analysis of Animal Studies. Neurocritical Care. https://doi.org/10.1007/s12028-026-02640-x

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02640-x

Keywords: traumatic brain injury, AMPA receptor antagonists, excitotoxicity, neuroprotection, perampanel, systematic review, meta-analysis, preclinical models, neurobehavioural outcomes, brain lesion severity, neuroinflammation, glutamate receptors